TUCSON, Ariz., July 22, 2020 /PRNewswire/ — This week the Association of American Physicians & Surgeons submitted additional evidence to a federal court for why interference with hydroxychloroquine (HCQ) should end by the Food & Drug Administration (FDA) and the Department of Health & Human Services (HHS), in AAPS v. FDA, No. 1:20-cv-00493-RJJ-SJB (W.D. Mich.).
“As confirmed by another recent study of thousands of patients at the Henry Ford Health System in Michigan, HCQ is both very safe and highly effective in treating COVID-19, reducing mortality by 50%,” AAPS informed the court in its filing. “Countries with underdeveloped health care systems are using HCQ early and attaining far lower mortality than in the United States, where [HHS and the FDA] impede access to HCQ.”
Yet most Americans are still unable to obtain HCQ for early treatment of COVID-19, and virtually no Americans are able to access it as preventive medicine. HCQ has been used safely for decades by travelers to protect against malaria, but Americans are dying from COVID-19 while HCQ is withheld from them.
“Citizens of the Philippines, Poland, Israel, and Turkey all have greater access to HCQ than American citizens do,” observes AAPS General Counsel Andrew Schlafly. “In Venezuela, HCQ is available over the counter without a prescription, while in the United States pharmacists are prevented from filling prescriptions for HCQ.” read more